Episode 334 -- District Court Dismisses Bulk of SEC Claims Against Solarwinds
The Justice Insiders Podcast - Human Beings: Cybersecurity's Most Fragile Attack Surface
FBI Lockbit Takedown: What Does It Mean for Your Company?
Privacy Officer's Roadmap: Data Breach and Ransomware Defense – Speaking of Litigation Video Podcast
Decoding Cyber Threats: Protecting Critical Infrastructure in a Digital World — Regulatory Oversight Podcast
No Password Required: Chief Adversarial Officer at Secure Yeti, a DEF CON Groups Global Ambassador, and a World-Class Awkward Hugger
2023 DSIR Deeper Dive: How International and Domestic Regulatory Enforcement Spotlights the Information Governance Tensions Between ‘There’ and ‘Here’ and Between ‘Keep’ and ‘Delete’
Marketing Minute with NP Strategy (Video): How to Respond to a Cyber Security Breach
Life With GDPR – Lessons Learned from The Singtel Opus Data Breach
No Password Required: Founder and Commissioner of the US Cyber Games, CEO of the Cyber Marketing Firm Katzcy, and Someone Who Values Perseverance Over Perfection
2023 DSIR Deeper Dive: State Privacy and Data Collection
Digital Planning Podcast Episode: When Cyber Attacks Hit Home
No Password Required: Threat Intelligence Analyst at Recorded Future, the Ransomware Sommelier, and a Guy With a Mildly Exciting Expense Account
Compliance & Disaster Preparedness
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 157: Sarah Glover, Maynard Nexsen Cybersecurity Attorney
Overview of Cybersecurity in Government Contracts
Episode 282 -- CISO and CCOs -- The Evolving Partnership
No Password Required: Threat Researcher at Cisco Talos and a Veteran of the Highest-Profile Cyber Incidents Who Roasts His Own Coffee Beans
Innovation in Compliance - Cybersecurity Today and Tomorrow with Patrick Hynds
Innovation in Compliance - The Role of Backup Systems in Cybersecurity Defense with Curtis Preston
Historically, many private equity firms have let their portfolio companies independently manage cybersecurity. Given the increase in data and cyber risks, sophistication of threat actors, and impact and cost of breaches,...more
On Feb. 27, the FBI and HHS issued a warning urging network defenders to review their joint advisory for healthcare organizations to protect against malicious activity after a ransomware group leader said it will be focusing...more
A privacy breach can have detrimental consequences for startups: A privacy breach may trigger legal consequences and regulatory scrutiny, especially for a startup that operates in areas with stringent data protection laws...more
News Briefs - House to Consider 19 Bills That Will Impact Healthcare System - The House of Representatives will consider 19 bills that affect various aspects of the U.S. healthcare system. The House Energy & Commerce...more
PE companies face increasing risk from cyber attackers, and regulators are holding directors personally accountable for cybersecurity failings. Cyberattacks targeting well-resourced businesses, especially those with...more
As we kick off 2023, we are optimistic that the healthcare private equity (PE) market will be resilient despite various headwinds. As you think ahead, please consider the issues and trends summarized below that may be helpful...more
On April 20, HaystackID shared an educational webcast developed to discuss best practices for handling big data and provide tangible field-experienced methods for data remediation. These best practices can be implemented at...more
HaystackID Educational Webcast The SEC recently proposed significant changes for PE reporting requirements. Whether these amendments are adopted or not, one thing is for sure; all alternative investment organizations are on...more
Cybersecurity breaches and threats are pervasive concerns for any entity storing valuable data or managing large sums of money: private investment funds are no exception. Recently three private equity firms suffered breaches...more
Innovation in the life sciences and health care industries is occurring at a dizzying pace. Five years ago, anti-PD-1 antibodies from Merck and BMS had yet to be approved, CAR-T therapies were still in small-scale clinical...more